25th European Symposium on Calcified Tissues entitled 'Defining Typologies in Osteoporosis', Harrogate, April 25, 1997 : Fast and slow bone losers: Relevance to the management of osteoporosis

dc.contributor.authorHough, S.
dc.date.accessioned2011-05-15T16:16:16Z
dc.date.available2011-05-15T16:16:16Z
dc.date.issued1998
dc.descriptionThe original publication is available at adisonline.com/aging
dc.description.abstractA low bone mineral density (BMD) is presently regarded as the most important risk factor for the development of osteoporosis. BMD is a function of peak bone mass attained during growth and subsequent age-related bone loss. BMD can be measured accurately and precisely, although the rate of bone loss is more difficult to assess. When axial BMD was measured, the rate of bone loss was shown to increase by 2- to 4-fold at the menopause. Although this rate varies markedly between individuals, it is symmetrically distributed, which argues against the existence of a subpopulation of fast bone losers. Levels of biochemical markers of bone turnover (e.g. osteocalcin, bone specific alkaline phosphatase, deoxypyridinoline) also increase markedly at the menopause. and individuals with a high turnover tend to lose bone more rapidly. Moreover, since increased bone resorption also results in qualitative changes regardless of BMD, a high bone turnover constitutes an independent risk factor. Currently, large intraindividual variations (10 to 40%) in levels of biochemical markers and assay errors still limit our ability to correctly classify individual patients as fast or slow bone losers. The routine use of these markers as a screening tool to predict the risk of osteoporosis in individuals is of limited value, although their selective use in therapeutic decision-making is more promising.
dc.description.versionConference Paper
dc.identifier.citationHough, S. 1998. 25th European Symposium on Calcified Tissues entitled 'Defining Typologies in Osteoporosis', Harrogate, April 25, 1997 : Fast and slow bone losers: Relevance to the management of osteoporosis. Drugs and Aging, 12, 1-7.
dc.identifier.citation12
dc.identifier.citationSUPPL. 1
dc.identifier.issn1170-229X (print)
dc.identifier.issn1179-1969 (online)
dc.identifier.urihttp://hdl.handle.net/10019.1/13703
dc.subjectalkaline phosphatase bone isoenzyme
dc.subjectbiochemical marker
dc.subjectdeoxypyridinoline
dc.subjectosteocalcin
dc.subjectaccuracy
dc.subjectbone atrophy
dc.subjectbone density
dc.subjectbone mass
dc.subjectbone mineral
dc.subjectbone turnover
dc.subjectconference paper
dc.subjecthuman
dc.subjectmedical decision making
dc.subjectmenopause
dc.subjectosteolysis
dc.subjectosteoporosis
dc.subjectpriority journal
dc.subjectrisk factor
dc.subjectscreening test
dc.title25th European Symposium on Calcified Tissues entitled 'Defining Typologies in Osteoporosis', Harrogate, April 25, 1997 : Fast and slow bone losers: Relevance to the management of osteoporosis
dc.typeConference Paper
Files